Virtual Library

Start Your Search

H. Ellidokuz



Author of

  • +

    P1.02 - Poster Session 1 - Novel Cancer Genes and Pathways (ID 144)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P1.02-020 - Evaluation Of Gene Expression Profiles For The Differential Diagnosis Of Lung Adenocarcinoma and Malignant Pleural Mesothelioma (ID 2381)

      09:30 - 16:30  |  Author(s): H. Ellidokuz

      • Abstract

      Background
      Squamous cell carcinoma is the most commonly diagnosed lung cancer type in Turkey; however lung adenocarcinoma diagnosis has risen among women and nonsmokers. MPM is common in Turkey because of the high asbestos exposition rates. Mostly, lung adenocarcinoma cannot be clearly differentiated from malignant pleural mesothelioma (MPM). Because of The limitations in the immunohistochemical methods there has been a growing interest in the use of gene expression profiling for diagnosis in many cancers. So we aimed to evaluate the gene expression profiles in tumor cells by using RT-PCR array, between two separate groups of lung adenocarcinoma and MPM patients.

      Methods
      Ten newly diagnosed patients with adenocarcinoma and paraffin-embedded tissues of 12 patients with MPM were included in this study without considering gender differences. Eight healthy individual were recruited as a control group. After processing the fresh samples of lung adenocarcinoma stored at -80°C for RNA isolation, cDNA synthesis and the expression of 84 genes were associated with DNA repair were analyzed with RT-PCR Array. Paraffin tissues of patients with MPM were deparaffinized and the same procedure was applied. Fold change values of gene expressions in each group are calculated in “SA Bioscience” data analysis expression page.

      Results
      ACBT, B2N, GADPH AND RPLPO genes were identified as housekeeping genes. Table 1 and 2 shows the comparisons of fold change values ​​of the gene expression differences between lung adenocarcinoma, MPM and control groups.

      Table 1: Fold changes ​​of the gene expressions of lung adenocarcinoma and MPM tumor cells comparing to control group
      Gene Adenocarcinoma/control fold change MPM/control fold change p value (comparing to control group) (adenocarcinoma/MPM)
      APEX2 1,6763 6,1243 >0.05 / >0.05
      BRCA1 9,5919 20,2646 >0.05 / 0,01558
      BRCA2 4,3804 10,8169 >0.05 / 0,012071
      CCNH 2,3922 4,4773 >0.05 / 0,032102
      CDK7 3,909 15,4192 >0.05 / 0,019161
      LIG4 2,2608 13,7822 0,044834 / >0.05
      MLH1 2,5581 7,5515 >0.05 / 0,013792
      MLH3 5,9579 15,4275 >0.05 / >0.05
      MSH3 2,2494 10,2785 >0.05 / >0.05
      MSH4 6,5356 12,0767 >0.05 / >0.05
      NEIL3 14,3334 80,5092 0,015299 / >0.05
      PARP1 0,9019 2,0543 >0.05 / >0.05
      PARP2 4,7127 7,4604 0,043874 /0,009579
      PARP3 2,3613 8,2119 >0.05 / 0,049911
      PMS1 1,8236 7,3582 >0.05 / 0,039034
      RAD50 2,6223 10,2765 >0.05 / 0,03758
      RAD51 2,6223 10,2765 >0.05 / >0.05
      RAD51B 4,3683 16,7622 >0.05 / >0.05
      RAD51D 3,2769 7,0688 >0.05 / >0.05
      RAD52 2,0126 5,1099 >0.05 / >0.05
      RPA3 2,8581 7,9353 >0.05 / >0.05
      PRKDC 0,5309 2,9778 >0.05 / >0.05
      SMUG1 6,7053 18,0914 >0.05 / >0.05
      TREX1 0,5115 4,1669 >0.05 / >0.05
      UNG 7,422 26,6752 0,027669 / 0,009662
      XPA 2,0485 8,8342 >0.05 / >0.05
      XRCC2 5,6758 17,6367 >0.05 / >0.05
      XRCC4 5,9765 17,0836 >0.05 / >0.05
      Table 2: The genes that fold change values ​​were statistically significant (p <0.05) in MPM and adenocarcinoma tumor cells relative to each other
      Gene MPM / Adenocarcinoma fold change P
      CDK7 4.39 <0.05
      MLH1 5.32 <0.05
      TREX1 9.29 <0.05
      PRKDC 7.64 <0.05
      XPA 5.54 <0.05
      PMS1 5.19 <0.05
      UNG 4.93 <0.05
      RPA3 2.97 <0.05

      Conclusion
      We showed that adenocarcinoma and MPM tumor cells have different expression profiles of DNA repair genes. Our study suggests that TREX1, PRKDC, PMS1 genes can be significant in support of differential diagnosis between MPM and lung adenocarcinoma.